
|Articles|June 1, 2001
- Pharmaceutical Executive-06-01-2001
- Volume 0
- Issue 0
Industry Under Investigation
FDA district offices may conduct site investigations to establish baseline information for sampling programs and tracking systems.
Advertisement
Articles in this issue
about 25 years ago
Emotion - The New Brand Integratorabout 25 years ago
For Love of the Gameabout 25 years ago
Field of Dreamsabout 25 years ago
Workshop: Access Optionsabout 25 years ago
Emotion - The New Brand Integratorabout 25 years ago
Rx-to-OTC: Unwanted Attentionabout 25 years ago
Emotion - Biotech Renaissance Manabout 25 years ago
Relocation: Coming to Americaabout 25 years ago
Stocks: Catching the Market Bluesabout 25 years ago
Gathering LightAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
3
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
4
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
5




